View Clinical Trial (Medical Research Study)

An Evaluation of the Efficacy and Safety of AL-46383A Ophthalmic Solution for the Treatment of Adenoviral Conjunctivitis - NCT00901693-76134(Clinical Trial 292140)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Fort Worth
State:  
TX
Zip Code: 76134
Conditions: Adenoviral Conjunctivitis
Purpose: The purpose of this study is to evaluate the safety and efficacy of AL-46383A Ophthalmic Solution for the treatment of adenoviral conjunctivitis.
Study summary:
Criteria: Inclusion Criteria: 1. At least one eye must have EITHER a positive adenovirus test (using the Adeno Detector™ for Adenoviral Conjunctivitis, Rapid Pathogen Screening, Inc.) OR a positive clinical diagnosis assessed by the Adenoviral Clinical Diagnostic Checklist. 2. Onset and development of ocular symptoms and/or signs of conjunctivitis ≤ 7 days prior to enrollment (Day 1) in either eye. 3. Be 6 years or older and of any race and either sex. 4. Must be able to understand and sign an informed consent form that has been approved by an Institutional Review Board/ Independent Ethics Committee (IRB/IEC). 5. Must agree to comply with the visit schedule and other requirements of the study. 6. Females who are not pregnant and are not lactating. All females of childbearing potential (those who are not pre-menarcheal, not postmenopausal or surgically sterile) may participate only if they have a negative urine pregnancy test prior to randomization, and if they agree to use adequate birth control methods to prevent pregnancy throughout the study. Exclusion Criteria: 1. Presence of sub-epithelial infiltrates at the Day 1 visit in either eye. 2. Presence of corneal opacity or any corneal abnormality at the Day 1 visit in either eye. 3. Contact lens wear during the course of the study. Participants requiring correction must have spectacles with appropriate correction. 4. Only one sighted eye or vision in either eye not correctable to 0.6 or better logMAR (using ETDRS chart) at the Day 1 visit. 5. Abnormal findings in the posterior pole of the retina or any media opacity found in a dilated fundus examination at the Day 1 (Screening/ Baseline) visit. 6. Suspected fungal, herpes, Chlamydia or Acanthamoeba infection, based on clinical observation. 7. Patients with a history of active uveitis or iritis in either eye. 8. Patients with a history of corneal transplant in either eye. 9. Presence of nasolacrimal duct obstruction at Day 1. 10. Use of specified prohibited medications.
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: February 17, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.